Hanlan Liu, Ph.D., MBA

Hanlan Liu, Ph.D., MBA has over 24 years of experience in the biopharmaceutical industry. Hanlan is currently the Senior Vice President of Rare Disease and Early Pipeline Research at Be Biopharma, where their responsibilities include overseeing the company's B cell platform, rare disease, and oncology research functions. Previously, they served as the Chief Scientific Officer/Chief Development Officer at Sperogenix Therapeutics, where they were responsible for developing and commercializing rare disease therapeutics in China. Prior to that, they held positions at KSQ Therapeutics, Catabasis Pharmaceuticals, Sanofi, Wyeth (now Pfizer), and Otsuka Pharmaceutical Companies (U.S.). Hanlan'sareas of expertise include drug metabolism and pharmacokinetics, formulation and analytical science, preclinical development, and clinical pharmacology.

Hanlan Liu, Ph.D., MBA received their Bachelor of Science degree in Biochemistry from Wuhan University in 1990. Hanlan then went on to pursue their Master of Science degree in Genetics from the same institution, which they completed in 1992. In 1993, Liu enrolled in Purdue University where they earned their Ph.D. in Medicinal Chemistry and Molecular Pharmacology in 1997. Later, in 2000, they obtained an MBA with Distinction, majoring in Corporate Finance from NYU Stern School of Business.